Rapport Therapeutics(RAPP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Rapport Therapeutics
RAPP.US
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc.
4.837 T
RAPP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    2026 AI Agent Economic Outlook: Reshaping AI Identity and the Flow of Network Value

    The 2026 AI Agent Economic Outlook predicts a significant shift from generative AI to agent action capabilities, marking the establishment of the "AI Agent Economy." Key trends include a new research paradigm of "Agent-Wrapping-Agent," a revolution in financial infrastructure from KYC to KYA, and economic model reconstruction to address hidden tax crises in open networks. The report highlights advancements in AI reasoning abilities, enabling complex research tasks and interdisciplinary exploration, exemplified by breakthroughs in protein design and fluid dynamics. The AWA architecture enhances research workflows through multi-agent collaboration and self-improvement mechanisms.

    CoinLive·
    CoinLive·

    AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

    AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

    marketscreener·
    marketscreener·

    How weight-loss drugs are destroying big snacking, erasing billions in sales

    The rise of GLP-1 weight-loss drugs is significantly impacting the food and beverage industry, leading to a projected $48 billion reduction in spending by 2034. Consumers are reducing their snacking frequency and appetite, with major brands like PepsiCo and Mondelez facing declining sales. Traditional marketing strategies are failing as appetite suppression alters consumer behavior, challenging the business models of companies reliant on high-volume sales. Fast-food spending has also dropped among GLP-1 users, indicating a fundamental shift in consumption patterns.

    Invezz·
    US
    PEP
    -0.17%
    US
    MDLZ
    -0.10%
    Invezz·
    US
    PEP
    -0.17%
    US
    MDLZ
    -0.10%

    Profusa launches Lumee Tissue Oxygen healthcare research offerings for immediate revenue generation with products available commercially.

    Commercially available research-use-only offerings now provide companies with the opportunity to quickly generate revenue through product and service sales. These offerings are designed specifically for research purposes and are accessible to businesses seeking to capitalize on this market.

    Unusual Whales·
    US
    PFSA
    +4.06%
    Unusual Whales·
    US
    PFSA
    +4.06%

    Atha Energy secures $25M in LIFE private placement for flow-through shares.

    The number of new COVID-19 cases in the country has increased by 15% in the past week, with over 20,000 new infections reported. Hospitalizations have also risen by 10% during the same period, with a total of 5,000 individuals currently receiving treatment. The vaccination rate continues to climb steadily, with over 40% of the population now fully vaccinated. Authorities are urging the public to adhere to safety protocols to prevent further spread of the virus.

    Unusual Whales·
    Unusual Whales·
    © 2026 Longbridge｜Disclaimer